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We have recently characterised the epidemiology of P. aeruginosa blood stream infection 
(BSI) in a large retrospective multicentre cohort study [1].  Utilising corresponding patient 
BSI isolates we aimed to characterise the genotypic virulence profile of the P. aeruginosa 
isolates that were associated with rapid death in the non-neutropenic host.  Five P. aeruginosa 
BSI episodes were identified from a larger cohort of P. aeruginosa BSI  episodes previously 
described  by McCarthy et al [1].  . The genotypic profile of another 5 isolates from this 
cohort in whom the non-neutropenic host had survived one year post the BSI was also 
analysed for comparison.  These isolates underwent Illumina whole genome sequencing and 
were de novo assembled using Spades VX.  Annotation was performed by the NCBI 
prokaryotic Genome Annotation Pipeline. A comprehensive suite of virulence genes was 
determined by utilising the Pseudomonas Genome Database  
(http://www.pseudomonas.com/) [2].  . For a gene to be considered present searching required 
100% of the gene to be present in the BLAST output. For both the Exolysin (ExlA) protein 
and the ExoU protein the reads were mapped in CLC Genomics Workbench V7.5.1  to the 
exlA (allele PSPA7_RS22085 in PA7 genome) or exoU (PA14_51530  allele in the PA14 
genome).  There was extensive conservation of virulence genes across all of the BSI isolates 
studied.  The exoU gene was found in two patients who died rapidly and in one patient that 
survived one year post BSI.  The higA and higB genes were detected in all isolates. The exlA 
gene was not detected in any of the isolates studied. These findings suggest that to cause a 
BSI that it is only the highly virulent P. aeruginosa isolate that succeeds. However the 
genetic armentarium is only one of many factors that result in death of the host.   Further 
phenotypic correlation is required.  
 
1.1 Highlights 
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• There was extensive conservation of virulence factors in all the P. aeruginosa BSI 
isolates studied 
• Genes making up the TTSS and the higA and higB genes were identified in all BSI 
isolates  
• The exlA gene was not identified in any of the BSI isolates studied. 
 
1.2 Key Words: Pseudomonas aeruginosa; blood stream infection; bacteremia; virulence; 
mortality 
 
1.3 Abbreviations 
BSI  Blood stream Infection 
ExlA Exolysin protein 
TTSS Type 3 protein secretion system  
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With the utilisation of whole genome sequencing we have been able to gain greater 
understanding of the genome of P. aeruginosa.  It is a large genome of 6.3 MB, containing on 
average more than 6175 genes [3].   The core genome represents on average 88% of the  
genome [4].  In comparison to the conserved core genome, the regions of the accessory 
genome are heterogeneous and contain genes identified from other bacteria [5].  Valot et al 
found that approximately one third of virulence genes are found in the accessory genome, the 
rest sitting in the core genome [4].   
The virulence genes of P. aeruginosa, outside of the cystic fibrosis setting, have been studied 
in a limited fashion in such cohorts as burn infections, urinary tract infections and blood 
stream infections (BSI) [6-8].  More recently Pena et al studied a large cohort of patients with 
P. aeruginosa BSI [9].  They were able to show that the genotypic presence of exoU was 
significantly associated with early death.  This was found to be more significant than the 
traditional patient risk factors also studied [9].  Elsen et al have recently described a toxin that 
causes hyper virulence in P. aeruginosa called ExlA [10].  This induces plasma membrane 
rupture in host cells [11].  Study in the context of patient outcomes has not been studied thus 
far.   
We have recently characterised the epidemiology of P. aeruginosa BSI in a large 
retrospective multicentre cohort study [1].  Utilising corresponding patient BSI isolates we 
wished to characterise the genotypic virulence profile of the P. aeruginosa isolates that 
caused rapid death in the non-neutropenic host.   
 
 
 
1.5 Methods 
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1.5.1 Study population 
P. aeruginosa BSI’s were studied retrospectively in a multicentre cohort study from the first 
of January 2008 to the first of January 2011 [1].   A BSI episode was identified as the 14 day 
time period from the date of the first positive blood culture.  Five hundred and ninety-five 
episodes of P. aeruginosa BSI were identified over the three year period.  After predefined 
exclusion criteria were applied, 388 monomicrobial non-recurrent BSI episodes from 388 
patients were available for further analysis.  This has been described in detail elsewhere [1].   
At 48 hours post the collection of the sentinel blood culture 17 patients, representing 17 BSI 
episodes had died [1].  Of these patients, six were neutropenic within the 14 day period prior 
to the BSI episode and were excluded from this virulence study.  In one patient their 
neutrophil count was not known and they were also excluded.  Of the remaining ten BSI 
episodes, five of the BSI isolates had been stored by the servicing laboratory and were 
available for further study.   
To obtain BSI isolates for comparison from non-neutropenic patients who had survived one 
year post BSI, 180 BSI episodes were identified from the previously mentioned cohort. Five 
BSI episodes were selected randomly from the cohort. The relevant BSI isolates had been 
stored by the servicing laboratory and were available for further study.   
1.5.2 Microbiological Methods 
Blood cultures were undertaken by the routine diagnostic laboratories using the BD 
BACTEC™ (43003-1) blood culture system (BD, North Ryde, Australia) with an incubation 
period of up to five days. Upon detection each culture positive blood sample was inoculated 
onto blood, chocolate and MacConkey agars and then incubated at 350C in either 5% CO2 or 
aerobic conditions. After overnight incubation the P. aeruginosa isolates were identified by 
the VITEK 2 system (bioMérieux Australia Pty Ltd, Baulkham Hills, Australia). Confirmed 
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P. aeruginosa isolates were stored at -800C using the Protect Microorganism Preservation 
System (Thermo Fisher Scientific Australia Pty Ltd, Thebarton, Australia) until transportation 
to a research laboratory. Upon receipt each isolate was resuscitated from -800C storage on 
Mueller-Hinton agar at 370C for 24 hours.  Antimicrobial susceptibility testing was performed 
by a microdilution method on the VITEK 2 system. Clinical and Laboratory Standards 
Institute breakpoints were used to define susceptibility or resistance to aztreonam, ticarcillin-
clavulanate, piperacillin-tazobactam, ceftazidime, cefepime, meropenem, ciprofloxacin and 
gentamicin [12].    
 
1.5.3 Whole Genome Sequencing and Analysis 
Paired end libraries of whole genomic DNA (QIA symphony DSP DNA Mini kit) of all 5 
isolates were prepared by the Nextera library protocol and sequenced by Illumina HiSeq2000 
or NextSeq500 (Illumina, San Diego, CA, USA). Sequences were trimmed in CLC Genomics 
Workbench 7.5.1.  All sequences were de novo assembled using SPAdes 3.8.1. Annotation 
was performed by the NCBI prokaryotic Genome Annotation Pipeline. The draft genomes 
were 4,654,913 to 6,618,287 bp long consisting of 112 to 400 contigs. (MWZF00000000.1 
Total number of genes: 6520 , CDS 6248, tRNA 50, non-coding RNA 4; MWZG00000000.2  
Total number of genes: 5197, CDS 5143,  tRNA 47 and non-coding RNA 3; 
MWZH00000000.1  Total number of genes: 5380 , CDS 5168, tRNA 43, non-coding RNA 4; 
MWZI00000000.1 Total number of genes: 4563 , CDS 4512,  tRNA 44 and non-coding RNA 
4; MWWL00000000.1 Total number of genes: 6502 , CDS 6440, tRNA 55, non-coding RNA 
4; SUB 3659983, SUB3660005, SUB3660009, SUB3660020, SUB3660023.  Contigs of the 
draft genomes were submitted to the Centre for Genomic epidemiology (http: //www.genomic 
epidemiology.org) to identify the resistance genes of each isolate with the database Resfinder 
2.1 [13] . The sequence type (ST) of each isolate was also identified by the Pseudomonas 
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aeruginosa MLST database 1.7 [14].  Two novel ST sequences were named upon submission 
to the MLST website (https://pubmlst.org/wolbachia/)[15]. A comprehensive suite of 
instrinsic virulence genes, found in wildtype PA01, was determined by utilising the 
Pseudomonas Genome Database  (http://www.pseudomonas.com/) [2].  For the HigB toxins, 
primer sequences were obtained and blasted to identify the gene product [16]. For a gene to 
be considered present searching required 100% of the gene to be present in the BLAST 
output. For both the Exolysin (ExlA) protein and the ExoU protein the reads were mapped in 
CLC Genomics Workbench V7.5.1  to the exlA (allele PSPA7_RS22085 in PA7 genome) or 
exoU (PA14_51530  allele in the PA14 genome).   
 
1.6 Results 
The first five P. aeruginosa isolates studied caused BSI in a non-neutropenic patient who 
experienced death within 48 hours of collection of the blood culture from which the bacteria 
was identified.  The host studied was not free of co-morbidities with two of the patients 
having metastatic small cell lung cancer and one patient having chronic lymphocytic 
leukaemia.  Two of the patients had received chemotherapy in the preceding 30 days and 
three patients recent corticosteroid therapy.  The BSI episodes were monomicrobial, non-
recurrent and phenotypically susceptible to all the antibiotics tested.  All BSI isolates 
originated from a presumed lung source of infection.  In two BSI episodes the patients did not 
receive empirical therapy that would have adequately covered the infecting P. aeruginosa 
isolate (Table 1, isolates 1-5).   
 
In comparison, the further five BSI isolates studied caused BSI in a non-neutropenic patient 
who was alive at one year post the collection of the blood culture from which the bacteria was 
identified.  Multiple host co-morbidities were again seen. Three of the five patients had either 
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an oncological or haematological condition. Only one patient had received chemotherapy in 
the preceding 30 days and one patient corticosteroids. All the BSI episodes were 
monomicrobial, non-recurrent and phenotypically susceptible to all antibiotic tested.  Three 
isolates originated from a lung source of infection and two isolates from a urinary tract 
infection.  All patients received empirical therapy that would have adequately covered the 
infecting P. aeruginosa isolate (Table 2, isolates 6-10). 
 
 
 Table 1: Patient characteristics of the five P. aeruginosa BSI episodes associated with rapid 
patient death 
 
Footnote 1: NSCLC (Non small cell lung cancer), COPD (Chronic obstructive pulmonary disease 
 
The ST types identified across the tenisolates were all unique and in two instances comprised 
novel genotypes on the PubMLST database. The genotypic antibiotic resistance profiles of 
each isolate are also described in Table 2.  Phenotypically the isolates were all found to be 
susceptible to ceftazidime, cefepime, ticarcillin-clavulanate, piperacillin-tazobactam, 
meropenem, gentamicin and ciprofloxacin. 
Patient 
Number Age Sex Acquisition Source
Pitt 
Score Co-morbidities
Medical Therapy in the last 
30 days Empirical Therapy
Death 
within 48 1 73 F HCAI Pneumonia 1 Metastatic NSCLC (Lung primary) Chemotherapy, corticosteroids Gentamicin, cefotaxime
2 54 M HCAI Lung Source 2 Metastatic NSCLC (Lung primary) Corticosteroids
Gentamicin, timentin, 
azithromycin
3 86 M HCAI  Lung source 12 Dementia, Chronic renal failure, Interstitial Lung Disease, 
atrial fibrillation
Corticosteroids Ceftriaxone, azithromycin
4 88 M HCAI Pneumonia 6 Asthma, COPD, hypertension, atrial fibrillation
Benzylpenicillin, ceftriaxone, 
azithromycin
5 89 F HCAI Pneumonia 2 Lung Cancer, Chronic lymphoctic leukaemia, hypertension Chlorambucil Vancomycin, gentamicin
Alive 1 year 6 64 M HAI Urinary Tract Infection 3 Prostate Cancer, Gout, COPD, IHD Ceftazidime
7 63 F CAI Pneumonia 5 Myeloma, Hypertension, GORD Timentin, gentamicin
8 93 F HAI Pneumonia 2 Asthma, IHD, Hypertension Timentin
9 66 M HCAI Pneumonia 3 Myelofibrosis, Sweets Syndrome, COPD, Hypertension Corticosteroids Timentin, gentamicin
10 49 M HAI Urinary Tract Infection 1 Recent brain trauma and secondary bleed Timentin, ciprofloxacin
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Table 2: MLST and antibiotic resistance genotype of the ten BSI isolates studied 
 
Footnote 2: Multilocus sequence type (ST) 
 
The genotypic virulence profiles of the isolates were determined as per Table 3.  There was 
extensive conservation of virulence genes across all ten of the BSI isolates studied. Threeof 
the isolates contained the exoU gene.  The higA and higB genes were detected in all isolates. 
The exlA gene was not detected in any of the isolates studied. 
 
 
 
 
 
 
 
Table 3: Genotypic virulence profile of the five BSI isolates studied 
Death within 48 hours                                                               Alive 1 year
Isolate Number 1 2 3 4 5 6 7 8 9 10
MLST type ST-569 ST-309 ST-898 Unknown ST Unknown ST ST-1639 ST-244 ST-671 ST-12 ST-931
Antibiotic Resistance 
Genotypic
Aminoglycoside aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b
Betalactamase blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50
blaPAO blaPAO blaPAO blaPAO blaPAO blaPAO blaPAO blaPAO blaPAO blaPAO
Chloramphenicol catB7 catB7 catB7 catB7 catB7
Fosfomycin fosA fosA fosA fosA fosA fosA fosA fosA fosA fosA
Phenotypic resistance Fully susceptible Fully susceptible Fully susceptible Fully susceptible Fully susceptible Fully Susceptible Fully Susceptible Fully Susceptible Fully Susceptible Fully Susceptible
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1.7 Discussion 
Isolates associated with rapid patient death Isolates associated with patient survival
System Virulence Factor Gene 1 2 3 4 5 6 7 8 9 10
Type 1 Secretion System Alkaline phosphatase aprF + + + + + + + + + +
Heme acquistion protein hasAP + + + - + + + + + +
Type 2 Secretion System Elastase lasB + + + + + + + + + +
Protease Precursor lasA + + + + + + + + + +
Non-hemolytic phospholipase C precursor pcLN + + + + + + + + + +
Protease piv + + + + + + + + + +
Lactonising lipase precursor lipA + + + + + + + + + +
Lipase lipC + + + + + + + + + +
Exotoxin A precursor toxA + + + - + + + + + +
Low-molecular weight alkaline phosphatase lapA + - + + - + + + + +
Metalloendopeptidase mep72 + + + + + + + + + +
Type 3 Secretion System Exoenzyme S exoS + - + + - + + - + +
Adenylate cyclase ExoY exoY + - + - - + + + + +
Exoenzyme T exoT + + + + + + + + + +
Exoenzyme U exoU - + - - + - - + - -
Secreted regulator of type III secretion genes exse + + + + + + + + + +
Type 4 Secretion System Amidase tse1 + + + + + + + + + +
Type 4 secretion system effector tse2 + + + + + + + + + +
Muramidase tse3 + + + + + + + + + +
Pyoverdin vgrG + + + + + + + + + +
3-oxo-C12-homoserine lactone acylase pvdQ + + + + + + + + + +
Type 5 Secretion System Esterase estA + + + + + + + + + +
Adhesive protein cupB5 + + + + + + + + + +
Exoprotease lep + + + + + + + + + +
Toxin/Antitoxin System Toxin/antitoxin system higA + + + + + + + + + +
Toxin/antitoxin system higB + + + + + + + + + +
Biofilm Alginate biosynthesis protein algX + + + + + + + + + +
GDP-mannose 6-hydrogenase algD + + + + + + + + + +
Poly(beta-d-mannuronate) lyase precursor algL + + + + + + + + + +
Alkaline metalloproteinase precursor aprA + + + + + + + + + +
Lectins Fructose-binding lectin PA-IIL lecB + + + + + + + + + +
Neuramindases Pseudoaminidase nan1 + - + + + + + + + +
Pseudoaminidase nan2 + + + + + + + + + +
Quorum Sensing ProteinsAutoinducor synthesis protein lasL + + + + + + + + + +
Transcriptional regulator lasR + + + + + + + + + +
Rhamnolipids Autoinducor synthesis protein rhll + + + + + + + + + +
Transcriptional regulator rhlR + + + + + + + + + +
Flagella Flagellin type B fliC + - + + + + + + + +
Polysaccharides Polysacharides psL + + + + + + + + + +
Excreted factor Hydrogen cyanide HCN + + + + + + + + + +
ExlA Secretion System Exolysin exlA - - - - - - - - - -
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The pathogenesis of P. aeruginosa is multifactorial as suggested by the large number of 
virulence determinants of this bacterium.  We have characterised the virulence gene profile of 
five BSI isolates associated with rapid patient death by whole genome sequencing.  This has 
been compared to the virulence gene profile of the BSI isolates of five patients that were alive 
at one year post BSI. Almost complete conservation of an extensive set of virulence genes 
was seen in both the isolates associated with patient death and also survival.  It may be that to 
cause an invasive infection it is only the fittest isolate that succeeds.  Futher phenotypic 
correlation is required to determine if there is any difference in genotypic expression by the 
BSI isolates in the two cohorts described.  
 
The characteristics of the larger patient cohort from which the BSI episodes came from is 
described in detail [1]. This was a patient cohort with significant co-morbidities, 
predominantly cardiovascular or haematological in origin and in whom receipt of medical 
therapy in the preceding 30 days occurred in 221 (57%) of the patients.  The most common 
therapy being either chemotherapy or corticosteroids [1].  Thus the patient characteristics of 
the five BSI episodes in this study associated with rapid death of the host have also been 
described in patients who did not die in the year post BSI.  We know from the literature that a 
higher PITT score, as seen in patient three, predicts a high risk of death from the BSI [17]. 
Also that a lung source would be considered a high risk bacteraemia for mortality [18].  
However to put this in context of the larger cohort described, not all patients with a lung 
source of BSI died [1].  The empirical therapy was considered inadequate in four of the five 
BSI’s associated with rapid host death that were studied [1]. The importance of adequate 
empirical therapy is still debated in the setting of this infection in the literature [19-21].  
Antibody protection to P. aeruginosa infection has also been described in animal models [22, 
23].  As such although the patients described that experienced rapid death would be higher 
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risk for death in the setting of this BSI, the BSI isolate must also play a role.  What are the 
genotypic virulence characteristics of the P. aeruginosa BSI isolate that is associated with 
rapid death?  
The literature has focused on the type 3 protein secretion system (TTSS) and virulence in P. 
aeruginosa infections.  El-Sohl et al performed a retrospective analysis of 85 cases of P. 
aeruginosa BSI at a tertiary care hospital.  Bacterial isolates were assayed in vitro for 
secretion of type 3 exotoxins.  They found that at least one of the TTSS proteins was detected 
in 37 of the 85 isolates (44%).  In addition the overall 30 day mortality was significantly 
greater on multivariate analysis in those isolates that were TTSS positive [24].  Pena et al 
looked at the genotypic relationship of the TTSS system in P. aeruginosa BSI’s and found a 
significant relationship between early mortality for the exoU genotype.  This was also 
associated with a moderately resistant susceptibility profile [9].  Only two of the five BSI 
isolates that were isolated from a patient with early mortality were exoU positive in the 
current study.  One of the five P.aeruginosa BSI isolates associated with patient survival at 
one year was also found to contain this gene.  
Recently two other significant toxins as a cause of virulence in this pathogen have been 
described.  A novel toxin exlA was also identified by Elsen et al, which induces plasma 
rupture in host cells [10].  Reboud further studied 18 isolates, including one BSI isolate, that 
contained this toxin and was TTSS negative [11].  They found that the behaviour and 
virulence traits of the exla+ strains were variable in the mouse and chicory leaf model [11].  
This toxin gene was not found in any of the BSI isolates we studied.  Wood et al have also 
recently characterised the HigB/HigA toxin-antitoxin system.  The HigB toxin was shown to 
reduce pyocynanin, pyochelin, swarming and biofilm formation [16].  The higA and higB 
genes were found in all the BSI isolates studied.   
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Focusing on acute infections caused by P. aeruginosa, limited numbers of genes related to 
pathogenicity have been described from different types of clinical isolates.  Consistent gene 
conservation has not been seen.  Faraji et al looked at burn wound isolates by targeted PCR 
and found that the prevalence rate of the virulence factors was as follows: tox A (36.9%), 
algD (70.1%), plcH (79%), plcN (63.1%), lasB (82%) and exoS (21.1%) [6].  Sebharwal et al 
looked at isolates from catheter associated urinary tract infections  by targeted PCR and found 
that the prevalence rate of virulence factors was toxA (100%), plcH (75%), lasB (75%), lasl 
(75%), lasR (75%), rhll (41.6%), rhlR (58.3%), aprA (16.6%), rhlAB (50%), fliC (58.3%) [7].  
We found a high degree of conservation of the virulence genes in all the BSI isolates studied. 
This was not dependent on whether the host died rapidly or not.   It may be that to cause a 
blood stream infection that it is only the fittest isolate that succeeds.  Wolfgang et al looked at 
18 P. aeruginosa strains from both the environment and clinical samples.  Two isolates of 
which were from blood.  Utilising whole-genome DNA microarray they found that upon 
examination of a gene set predicted to play a role in virulence, there was a high level of 
conservation across the isolates (97%) [25].  Our study looking at BSI isolates supports this 
finding.   
The traditional view of P. aeruginosa pathogenicity was that virulence factors were the most 
important factors in the infective process.   Recent work by Turner et al involving translation 
research in mouse models has changed the thinking relating to virulence [26].  This study 
combined both mutant fitness profiling and transcriptome profiling to study which P. 
aeruginosa genes were important for acute or chronic infections.  For most classes of genes, 
including virulence genes, this analysis found that there was little association between 
transcript abundance and the contribution of the corresponding gene towards overall fitness.  
However for certain metabolic genes these factors were strongly associated.  Interestingly it 
would seem that it is the environment that P. aeruginosa finds itself in that drives the 
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metabolic pathways and subsequent expression of virulence factors as part of a process of 
survival.   
Limitations of the current study include lack of correlation of phenotypic expression of 
virulence with the genotypic findings.  It would have also been ideal if a larger selection of 
BSI isolates could have been studied.   
 
1.8 Conclusions 
In conclusion this study places the genotypic detection of virulence factors of P. aeruginosa 
BSI isolates in the clinical context.  Five P. aeruginosa BSI isolates that were associated with 
rapid patient mortality have had characterisation of their virulence gene profile.   Five P. 
aeruginosa BSI isolates that were associated with patient survival at one year were also 
characterised as a comparator group. There was extensive conservation of virulence genes 
across the isolates. Threeof the isolates contained the exoU gene which was not limited to the 
host who experienced rapid death.  The higA and higB genes were detected in all isolates. The 
exlA gene was not detected in any of the isolates studied.  These findings may reflect that to 
cause both a blood stream infection that it is only the highly virulent P. aeruginosa isolate 
that succeeds.  Futher phenotypic correlation is required to determine if there is any 
difference in genotypic expression by the BSI isolates that were associated with rapid death 
of the host and those BSI isolates associated with host survival at one year.  
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1.1 Highlights 
• There was extensive conservation of virulence factors in all the P. aeruginosa BSI 
isolates studied 
• Genes making up the TTSS and the higA and higB genes were identified in all BSI 
isolates  
• The exlA gene was not identified in any of the BSI isolates studied. 
 
